FibroGen Inc (FGEN) CEO Sells $2,106,257.04 in Stock

FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 39,636 shares of the company’s stock in a transaction dated Thursday, March 8th. The stock was sold at an average price of $53.14, for a total transaction of $2,106,257.04. Following the completion of the sale, the chief executive officer now directly owns 2,907,425 shares of the company’s stock, valued at $154,500,564.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of FibroGen Inc (FGEN) opened at $55.45 on Friday. The company has a market cap of $4,501.22, a PE ratio of -31.33 and a beta of 1.76. FibroGen Inc has a 1 year low of $22.75 and a 1 year high of $63.00. The company has a current ratio of 9.70, a quick ratio of 9.70 and a debt-to-equity ratio of 0.17.

How to Become a New Pot Stock Millionaire

Hedge funds have recently added to or reduced their stakes in the business. Bank of Montreal Can lifted its position in shares of FibroGen by 2,097.2% during the fourth quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 3,041 shares during the last quarter. Fortaleza Asset Management Inc. increased its holdings in shares of FibroGen by 95.0% during the fourth quarter. Fortaleza Asset Management Inc. now owns 3,490 shares of the biopharmaceutical company’s stock valued at $165,000 after acquiring an additional 1,700 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of FibroGen by 41.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 1,147 shares in the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of FibroGen by 112.6% during the third quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock valued at $237,000 after acquiring an additional 2,336 shares in the last quarter. Finally, Paloma Partners Management Co acquired a new position in shares of FibroGen during the fourth quarter valued at about $255,000. 60.54% of the stock is owned by institutional investors and hedge funds.

FGEN has been the subject of several analyst reports. TheStreet raised shares of FibroGen from a “d” rating to a “c-” rating in a research report on Tuesday, February 27th. ValuEngine raised shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub raised shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Leerink Swann reissued an “outperform” rating and set a $88.00 price target (up from $80.00) on shares of FibroGen in a research report on Wednesday, February 28th. Finally, Zacks Investment Research lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Monday, March 5th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $66.67.

ILLEGAL ACTIVITY WARNING: “FibroGen Inc (FGEN) CEO Sells $2,106,257.04 in Stock” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://sportsperspectives.com/2018/03/10/fibrogen-inc-fgen-ceo-sells-2106257-04-in-stock.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply